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Variable Preprocedure Postprocedure*
6-Month
Follow-up*
N 126 126 113
Lesion length, mm 11.203.77 - -
Reference diameter, mm 3.060.31 3.090.26 3.010.29
MLD, mm 0.920.40 2.670.28 2.450.44
% DS 69.912.3 13.57.8 18.313.6
Acute gain, mm - 1.730.45 -
% acute recoil, mm - 6.66.2 -
Late lumen loss, mm - - 0.210.34
*In-scaffold
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Background: Bioresorbable scaffold is a novel approach that provides transient
vessel support with drug delivery capability without the long-term limitations of
metallic drug-eluting stents. The everolimus-eluting bioresorbable scaffold
(ABSORB; Abbott vascular, CA, USA) has been shown to be effective in the context
of ﬁrst-in-man trials including simple lesion(s). However, the effect of ABSORB
implantation in more complex patients cannot be directly extrapolated from these
ﬁndings. We sought to evaluate the impact of this novel technology on the short- and
intermediate- term clinical outcomes in a real-life population with complex lesions.
Methods: Since September 1st 2013, our institution commenced the use of
ABSORB scaffold in patients with complex lesions including a long lesion
(>32mm in length), a calciﬁed lesion, a bifurcation lesion and a large vessel with
up to 4mm in diameter. Patients presenting with stable angina, unstable angina and
non-ST elevation myocardial infarction were included. In total 300 patients pre-
senting with de novo complex lesions will be treated exclusively with ABSORB
scaffolds.
Results: Up to May 1, 2013, 137 patients were included in the study. In total 248
scaffolds were implanted, with a procedural success rate of 95%, in the lesions
including 40 bifurcations and 11 chronic total occlusions. In 52 patients (53 lesions),
more than one scaffold was implanted with overlap. An interim analysis of the pop-
ulation at one month revealed no MACE event except for one myocardial infarction.
The enrolment is ongoing while the updated one-month and 6-month data on the
occurrence of death, MI, repeat revascularization and scaffold thrombosis are
currently being collected and will be presented at the time of the meeting. Survival
information will be obtained from municipal civil registries.
Conclusions: The short-term and intermediate-term clinical safety and efﬁcacy of the
ABSORB scaffold in complex lesions will be presented at the meeting.
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Background: The ABSORBTM bioresorbable vascular scaffold (BVS) (Abbott
Vascular, Santa Clara, CA, USA) is a resorbable polymeric scaffold that provides
temporary scaffolding and everolimus drug delivery. The resorption of the BVS
potentially overcomes the limitations of metallic stents. There is limited data on its use
in daily clinical practice, especially in acute coronary syndrome (ACS) patients and
complex lesions. We assessed the safety and performance of ABSORB BVS
implantation in a selected patient cohort comparable with "real world" situation.
Methods: All patients who had undergone percutaneous coronary intervention (PCI)
with ABSORB BVS implantation in our centre between August 2012 and June 2013
were included in this registry. Clinical outcome were deﬁned as cardiac death,
myocardial infarction (MI), target vessel revascularization (TVR), target lesion rav-
ascularization (TLR), scaffold thrombosis (ST), and major adverse cardiac event
(MACE; composite of cardiac death, MI and TVR). In addition, Quanitative Coronary
Analysis including angiographic success rate will be performed and available at TCT.
Results: A total of 117 patients (136 lesions) were treated with an ABSORB BVS.
The indication for PCI was stable angina in 53 patients (45%), non ST-segment
elevation acute coronary syndrome (NSTE-ACS) in 38 patients (33%), and ST-
segment elevation myocardial infarction (STEMI), in the setting of primary PCI, in 20
patients (17%). In total 64% of the 136 lesions had type B2 or C ACC/AHA classi-
ﬁcation, including 9 chronic total occlusions, 2 left main, 4 ostial, 3 long (>50 mm)
and 8 complex bifurcation lesions treated with Tryton bifurcation stent and BVS. At
least 1 month follow-up was available in 94 patients (median follow up 54 days; Q1-
Q3: 40-67). MACE occurred in 4 patients (4.2%). Two patients experienced MI due to
subacute scaffold thrombosis and two patients needed target vessel revascularization,
including one target lesion, due to recurrent angina pectoris.
Conclusions: In a patient population reﬂecting daily clinical practice, including high-
risk lesions and high-risk patients, the ABSORB BVS had good short term results.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-431
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Background: By design, drug-eluting bioresorbable scaffolds have been developed as
an alternative to metallic stents in order to provide temporary vascular scaffolding,
prevent vessel recoil and inhibit late clinical events due to excessive neointimal
hyperplasia formation including restenosis and lesion revascularization. The DES-
olve bioresorbable scaffold (Elixir Medical Co., Sunnyvale, CA) is a novel device
combining a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and a potent anti-proliferative sirolimus metabolite Novolimus, with a drug
dose of 5 mcg per mm of scaffold length. Our objective was to report serial QCA results
from the prospective, non-randomized, single-arm multicentre DESolve Nx trial.
Methods: A total of 126 patients/lesions were enrolled in 13 sites in Europe, New
Zealand and Brazil. Lesion criteria were single de novo lesion <14 mm in length,
located in native coronary vessels 2.75-3.50 mm in diameter, with stenosis between
50-90% and TIMI ﬂow 2. The study device was available in 3.00, 3.25 and 3.50 mm
in diameter and 14 and 18 mm in length. All patients were assigned to angiographic
follow-up at 6 months. Quantitative coronary angiography (QCA) analysis was
performed at an independent angiographic core laboratory.
Results: Overall, mean age was 62 years and 21% had diabetes. Target lesions were
evenly distributed in LAD, LCx and RCA, and most lesions were classiﬁed as type B
(71%) according to the ACC/AHA classiﬁcation. During procedure, the study device was
successfully implanted in 122/126 cases (97%). Serial QCA results are shown in the Table.Conclusions: Angiographic results of the novel DESolve bioresorbable scaffold
showed promising results in de novo coronary artery lesions including relatively
low in-scaffold late lumen loss, a surrogate of neointimal hyperplasia, at 6-month
follow-up.
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Background: The use of bioresorbable vascular scaffolds (BVS) has largely been
restricted to simple lesions with a relatively small number of patients treated with
complex lesions. The aim of this study was to evaluate the device success and short-
term clinical outcomes of BVS in 'real world' patients including those with complex
coronary lesions.
Methods: All consecutive patients treated with BVS between May 2012 and June
2013 at 2 centers were included in this analysis.
Results: A total of 123 lesions in 82 patients (87.8% male, mean age 64.6 years) were
treated with BVS. Complex lesions were distributed as follows: long lesion >20mm
(n¼83), bifurcation lesions (n¼49), calciﬁed lesions (n¼42), chronic total occlusions
(n¼9) and in-stent restenoses (n¼7), one feature could be present inmore than one lesion.
Intracoronary vascular ultrasound and optical computed tomographywere used in 85.4%
and 20.3% of cases, respectively. Pre-dilation was performed in 98.4%, while post-
dilation (mean 21.5 atmosphere) was utilized in all cases. Rotablation or scoring balloon
was used in 22.0%. Device success was achieved in 99.2%. At median follow-up of 147acts/POSTER/Bioresorbable Vascular Scaffolds B133
